MA33751B1 - Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1 - Google Patents
Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1Info
- Publication number
- MA33751B1 MA33751B1 MA34869A MA34869A MA33751B1 MA 33751 B1 MA33751 B1 MA 33751B1 MA 34869 A MA34869 A MA 34869A MA 34869 A MA34869 A MA 34869A MA 33751 B1 MA33751 B1 MA 33751B1
- Authority
- MA
- Morocco
- Prior art keywords
- orl
- compounds
- treatment
- spirobridine
- receptor antagonists
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 108010020615 nociceptin receptor Proteins 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 2
- 206010033307 Overweight Diseases 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010027603 Migraine headaches Diseases 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne un antagoniste de récepteur orl-1 de formule i, ses utilisations et procédés de préparation. Des antagonistes de orl-1 sont jugés utiles dans le traitement de la dépression et/ou le traitement du surpoids, de l'obésité, et/ou le maintien du poids après un traitement du surpoids ou de l'obésité. Certains composés ont également montré dans des modèles animaux que les composés de la présente invention sont utiles pour le traitement de migraines.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382246 | 2009-11-16 | ||
| US29862910P | 2010-01-27 | 2010-01-27 | |
| PCT/US2010/056180 WO2011060035A1 (fr) | 2009-11-16 | 2010-11-10 | Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33751B1 true MA33751B1 (fr) | 2012-11-01 |
Family
ID=41728051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA34869A MA33751B1 (fr) | 2009-11-16 | 2012-05-14 | Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1 |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US8232289B2 (fr) |
| EP (1) | EP2501703B1 (fr) |
| JP (1) | JP5680101B2 (fr) |
| KR (1) | KR101363830B1 (fr) |
| CN (1) | CN102612520B (fr) |
| AR (1) | AR078863A1 (fr) |
| AU (1) | AU2010319581C1 (fr) |
| CA (1) | CA2796161C (fr) |
| CO (1) | CO6541545A2 (fr) |
| CR (1) | CR20130087A (fr) |
| DK (1) | DK2501703T3 (fr) |
| DO (1) | DOP2012000135A (fr) |
| EA (1) | EA020848B1 (fr) |
| EC (1) | ECSP12011902A (fr) |
| ES (1) | ES2435814T3 (fr) |
| HN (1) | HN2012001011A (fr) |
| HR (1) | HRP20130967T1 (fr) |
| IL (1) | IL219370A (fr) |
| JO (1) | JO2887B1 (fr) |
| MA (1) | MA33751B1 (fr) |
| ME (1) | ME01537B (fr) |
| MX (1) | MX2012005691A (fr) |
| MY (1) | MY160665A (fr) |
| NZ (1) | NZ600006A (fr) |
| PE (1) | PE20121430A1 (fr) |
| PH (1) | PH12012500969A1 (fr) |
| PL (1) | PL2501703T3 (fr) |
| PT (1) | PT2501703E (fr) |
| RS (1) | RS53018B (fr) |
| SI (1) | SI2501703T1 (fr) |
| TW (1) | TWI465453B (fr) |
| UA (1) | UA107943C2 (fr) |
| WO (1) | WO2011060035A1 (fr) |
| ZA (1) | ZA201202967B (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ767139A (en) | 2009-12-04 | 2022-08-26 | Sunovion Pharmaceuticals Inc | Multicyclic compounds and methods of use thereof |
| JP2013540145A (ja) * | 2010-10-21 | 2013-10-31 | ウニベルシテート デス ザールランデス | コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤 |
| TWI582096B (zh) * | 2011-12-06 | 2017-05-11 | 美國禮來大藥廠 | 用於酒精依賴及濫用處理之４',５'－二氫螺［哌啶－４,７'－噻吩并[２，３－c]哌喃］化合物 |
| TW201416370A (zh) | 2012-07-31 | 2014-05-01 | Lilly Co Eli | 用於治療焦慮之ｏｒｌ－１受體拮抗劑 |
| WO2014053450A1 (fr) | 2012-10-02 | 2014-04-10 | Bayer Cropscience Ag | Composés hétérocycliques utilisés comme pesticides |
| EP2919788A4 (fr) | 2012-11-14 | 2016-05-25 | Univ Johns Hopkins | Méthodes et compositions pour le traitement de la schizophrénie |
| TW201607923A (zh) | 2014-07-15 | 2016-03-01 | 歌林達有限公司 | 被取代之氮螺環（４．５）癸烷衍生物 |
| JO3638B1 (ar) * | 2015-09-09 | 2020-08-27 | Lilly Co Eli | مركبات مفيدة في تثبيط ror - جاما- t |
| KR20190065246A (ko) | 2016-07-29 | 2019-06-11 | 선오비온 파마슈티컬스 인코포레이티드 | 화합물 및 조성물 및 이들의 용도 |
| US10196403B2 (en) | 2016-07-29 | 2019-02-05 | Sunovion Pharmaceuticals Inc. | Compounds and compositions and uses thereof |
| WO2018151861A1 (fr) | 2017-02-16 | 2018-08-23 | Sunovion Pharamaceuticials Inc. | Procédés de traitement de la schizophrénie |
| PL3589638T3 (pl) | 2017-03-02 | 2021-09-27 | Eli Lilly And Company | Związki użyteczne do hamowania ror-gamma-t |
| EP3589637B1 (fr) * | 2017-03-02 | 2021-04-14 | Eli Lilly and Company | Composés utiles pour l'inhibition du ror-gamma-t |
| JP7191085B2 (ja) | 2017-08-02 | 2022-12-16 | サノビオン ファーマシューティカルズ インク | イソクロマン化合物およびその使用 |
| EP3752508A1 (fr) | 2018-02-16 | 2020-12-23 | Sunovion Pharmaceuticals Inc. | Sels, formes cristallines et procédés de production associés |
| US11618746B2 (en) | 2018-12-17 | 2023-04-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| MX2021010880A (es) | 2019-03-14 | 2022-01-18 | Sunovion Pharmaceuticals Inc | Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas. |
| WO2021211489A1 (fr) | 2020-04-14 | 2021-10-21 | Sunovion Pharmaceuticals Inc. | (s)-(4,5-dihydro-7 h-thiéno[2,3-c]pyran-7-yl)-n-méthylméthanamine pour le traitement de troubles neurologiques et psychiatriques |
| AR123355A1 (es) | 2020-08-26 | 2022-11-23 | Vertex Pharma | Inhibidores de apol1 y métodos para usar los mismos |
| US20250171459A1 (en) * | 2022-02-08 | 2025-05-29 | Vertex Pharmaceuticals Incorporated | 2-methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL96507A0 (en) | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
| AU1948601A (en) | 1999-12-06 | 2001-06-12 | Euro-Celtique S.A. | Triazospiro compounds having nociceptin receptor affinity |
| ATE403429T1 (de) | 2001-04-18 | 2008-08-15 | Euro Celtique Sa | Spiropyrazol-verbindungen |
| WO2002088089A1 (fr) | 2001-04-19 | 2002-11-07 | Banyu Pharmaceutical Co., Ltd. | Derives de spiropiperidine, antagonistes du recepteur de nociceptine les contenant en tant qu'ingredient actif et compositions medicinales |
| ATE396995T1 (de) | 2001-07-23 | 2008-06-15 | Banyu Pharma Co Ltd | 4-oxoimidazolidin-2-spiro piperidin derivat |
| JP2005519921A (ja) * | 2002-01-28 | 2005-07-07 | ファイザー株式会社 | Ｏｒｌ−１受容体リガンドとしてのｎ置換スピロピペリジン化合物 |
| JPWO2003095427A1 (ja) | 2002-05-10 | 2005-09-15 | 大正製薬株式会社 | スピロ環化合物 |
| US6995168B2 (en) | 2002-05-31 | 2006-02-07 | Euro-Celtique S.A. | Triazaspiro compounds useful for treating or preventing pain |
| MXPA05002622A (es) | 2002-09-09 | 2005-09-08 | Johnson & Johnson | Derivados de 1,3,8,-triazaespiro [4.5]decan-4-ona sustituidos con hidroxialquilo utiles para el tratamiento de desordenes mediados por el receptor opioide huerfano. |
| WO2005016913A1 (fr) * | 2003-08-19 | 2005-02-24 | Pfizer Japan, Inc. | Composes de tetrahydroisoquinoline ou d'isochroman en tant que ligands du recepteur orl-1 pour le traitement de la douleur et des troubles du systeme nerveux central |
| DE10360792A1 (de) * | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| BRPI0509307A (pt) * | 2004-03-29 | 2007-09-04 | Pfizer | compostos de alfa aril ou heteroaril metil beta piperidino propanamida como antagonistas do receptor orl1 |
| DE102004039382A1 (de) * | 2004-08-13 | 2006-02-23 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| EP2020414A1 (fr) | 2007-06-20 | 2009-02-04 | Laboratorios del Dr. Esteve S.A. | Derivés spiro[piperidine-4,4'-thieno[3,2-c]pyran] et composés similaires en tant que inhibiteurs du recepteur sigma pour le traitement de pyschose |
| PT2260042E (pt) | 2008-03-27 | 2011-12-06 | Gruenenthal Gmbh | Derivados de ciclo-hexano espirocíclicos substituídos |
-
2010
- 2010-10-11 UA UAA201205367A patent/UA107943C2/uk unknown
- 2010-11-02 AR ARP100104035A patent/AR078863A1/es active IP Right Grant
- 2010-11-03 JO JO2010386A patent/JO2887B1/en active
- 2010-11-05 TW TW099138241A patent/TWI465453B/zh not_active IP Right Cessation
- 2010-11-10 CN CN201080051850.4A patent/CN102612520B/zh not_active Expired - Fee Related
- 2010-11-10 WO PCT/US2010/056180 patent/WO2011060035A1/fr not_active Ceased
- 2010-11-10 EA EA201290352A patent/EA020848B1/ru not_active IP Right Cessation
- 2010-11-10 PE PE2012000659A patent/PE20121430A1/es active IP Right Grant
- 2010-11-10 NZ NZ600006A patent/NZ600006A/en not_active IP Right Cessation
- 2010-11-10 EP EP10782482.3A patent/EP2501703B1/fr active Active
- 2010-11-10 US US12/943,187 patent/US8232289B2/en not_active Expired - Fee Related
- 2010-11-10 RS RS20130485A patent/RS53018B/sr unknown
- 2010-11-10 HR HRP20130967AT patent/HRP20130967T1/hr unknown
- 2010-11-10 SI SI201030388T patent/SI2501703T1/sl unknown
- 2010-11-10 PL PL10782482T patent/PL2501703T3/pl unknown
- 2010-11-10 MY MYPI2012002117A patent/MY160665A/en unknown
- 2010-11-10 ES ES10782482T patent/ES2435814T3/es active Active
- 2010-11-10 MX MX2012005691A patent/MX2012005691A/es active IP Right Grant
- 2010-11-10 DK DK10782482.3T patent/DK2501703T3/da active
- 2010-11-10 ME MEP-2013-118A patent/ME01537B/me unknown
- 2010-11-10 CA CA2796161A patent/CA2796161C/fr not_active Expired - Fee Related
- 2010-11-10 KR KR1020127012498A patent/KR101363830B1/ko not_active Expired - Fee Related
- 2010-11-10 PH PH1/2012/500969A patent/PH12012500969A1/en unknown
- 2010-11-10 JP JP2012538935A patent/JP5680101B2/ja not_active Expired - Fee Related
- 2010-11-10 PT PT107824823T patent/PT2501703E/pt unknown
- 2010-11-10 AU AU2010319581A patent/AU2010319581C1/en not_active Ceased
-
2012
- 2012-04-23 ZA ZA2012/02967A patent/ZA201202967B/en unknown
- 2012-04-23 IL IL219370A patent/IL219370A/en not_active IP Right Cessation
- 2012-05-04 CO CO12073055A patent/CO6541545A2/es active IP Right Grant
- 2012-05-11 DO DO2012000135A patent/DOP2012000135A/es unknown
- 2012-05-11 HN HN2012001011A patent/HN2012001011A/es unknown
- 2012-05-14 MA MA34869A patent/MA33751B1/fr unknown
- 2012-05-16 EC ECSP12011902 patent/ECSP12011902A/es unknown
-
2013
- 2013-02-26 CR CR20130087A patent/CR20130087A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA33751B1 (fr) | Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1 | |
| PT2501704E (pt) | Compostos de espiropiperidina como antagonistas do receptor orl-1 | |
| DE602008005771D1 (de) | Disubstituierte alkyl-8-azabicycloä3.2.1üoktan-verbindungen als mu-opioid-rezeptorantagonisten | |
| MA34650B1 (fr) | Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane | |
| WO2006029153A3 (fr) | Antagonistes de recepteurs cgrp d'anilide spirolactame monocyclique | |
| MA31158B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
| PH12012501640A1 (en) | Novel compounds as opioid receptor modulators | |
| WO2008112159A3 (fr) | Antagonistes des récepteurs cgrp d'anilide spirolactame monocyclique | |
| MA34300B1 (fr) | Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10 | |
| PH12014502280A1 (en) | Indole and indazole compounds that activate ampk | |
| MY148544A (en) | Pyridyl piperidine orexin receptor antagonists | |
| DE602005020472D1 (de) | Tricyclische anilid-spirohydantoin-cgrp-rezeptorantagonisten | |
| JO3346B1 (ar) | مواد مضادة C5aR | |
| MA32131B1 (fr) | Antagonistes aminoalkylbiphényle n, n' disubstitués des récepteurs d2 de la prostaglandine | |
| DE602005020655D1 (de) | Carboxamid-spirolactam-cgrp-rezeptor-antagonisten | |
| MA33155B1 (fr) | Composes organiques et leurs utilisations | |
| MA31766B1 (fr) | Composés organiques | |
| ATE537153T1 (de) | Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors | |
| ATE517106T1 (de) | Kondensierte spiropiperidine als modulatoren muskarinartiger rezeptoren | |
| MA31521B1 (fr) | Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central | |
| MA34545B1 (fr) | Co-cristaux et sels d'inhibiteurs de ccr3 | |
| ATE518852T1 (de) | Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten | |
| CH707539A8 (fr) | Alliage d'or rose pour pièce d'horlogerie. | |
| DE602007004327D1 (de) | Einen azepin-kern enthaltende antagonisten des histaminrezeptors | |
| GB2498268A (en) | Silicone protectant compositions |